VR Logo

Lucid Diagnostics Inc. (LUCD) download report

Healthcare | Medical Devices & Equipment

Lucid Diagnostics Inc. (LUCD) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.

IPO Date: 14-Oct-2021

Chairman & CEO: Dr. Lishan Aklog M.D.

CFO, Pres & Sec.: Mr. Dennis M. McGrath CPA


Country: United States

Headquarters: New York, NY

Website: https://www.luciddx.com

Key Facts

Market cap: $88.86 Mln

Revenue (TTM): $200.80 Mln

Earnings (TTM): $-36.69 Mln

Cash: $53.66 Mln

Total Debt: $2.22 Mln

Insider's Holding: 78.38%

Liquidity: Low

52 Week range: $1.70 - 13.52

Shares outstanding: 38,138,000

Stock Performance

Time Period Lucid Diagnostics (LUCD) S&P BSE Sensex* S&P Small-Cap 600*
1 month8.37-4.06-8.00
3 months-30.65-11.73-13.65
1 Year--1.94-17.19
3 Years--10.276.10
5 Years--11.385.87
10 Years--11.859.84
As on 01-Jul-2022 *As on 05-Jul-2022